Active, not recruitingPhase 1NCT04685473

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors

Studying Catastrophic antiphospholipid syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Taivex Therapeutics Corporation
Intervention
T-1101 (Tosylate)(drug)
Enrollment
24 enrolled
Eligibility
20 years · All sexes
Timeline
20212026

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04685473 on ClinicalTrials.gov

Other trials for Catastrophic antiphospholipid syndrome

Additional recruiting or active studies for the same condition.

See all trials for Catastrophic antiphospholipid syndrome

← Back to all trials